Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia.
Jin Ju KimJi Eun JangHyeon Ah LeeMi Ri ParkHye Won KookSeung Tae LeeJong Rak ChoiYoo Hong MinSaeam ShinJune-Won CheongPublished in: Annals of laboratory medicine (2023)
Our highly sensitive and accurate NGS-MRD panel can be readily used to monitor most AML patients in clinical practice, including patients without gene rearrangement. In addition, this NGS-MRD panel may allow the detection of newly emerging clones during clinical relapse, leading to more reliable prognoses of AML.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute myeloid leukemia
- clinical practice
- prognostic factors
- copy number
- peritoneal dialysis
- high resolution
- patient reported outcomes
- transcription factor
- mass spectrometry
- allogeneic hematopoietic stem cell transplantation
- patient reported
- fluorescent probe
- loop mediated isothermal amplification